Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.724438
Title: In vitro generation of cytotoxic T cells with potential for adoptive tumour immunotherapy
Author: Khalaf, Wafaa Seifalnaser Sedik
ISNI:       0000 0004 6424 8742
Awarding Body: University of Leicester
Current Institution: University of Leicester
Date of Award: 2017
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Thesis embargoed until 22 Sep 2018
Access from Institution:
Abstract:
Multiple myeloma (MM) is a life-threatening haematological malignancy, which is rarely curable by conventional therapies. Immunotherapy, using autologous antigen specific cytotoxic T-lymphocytes (ASCTL), may represent a useful adjunct therapy for MM. In this study, I assessed the ability of previously described hybrid cell lines, generated by chemical fusion of myeloma tumour cells and the EBV B-lymphoblastoid cell line (EBV B-LCL) HMy2, to induce ASCTL in vitro from peripheral blood lymphocytes from patients with MM (and from healthy individuals). The tumour associated antigens (TAAs) hTERT, MUC1, MAGE-C1 and CS1 were selected as potential inducers of ASCTL, based on their prevalence of expression in MM patients. Expression of these TAAs was assessed in four B-LCL/myeloma hybrid cell lines, using real time PCR and flow cytometry, and two of the hybrid cell lines were selected as in vitro stimulator cell lines in long-term activated T-cell cultures, using PBMCs from HLA-A2+ healthy donors and multiple myeloma patients. Induction of ASCTLs was assessed by HLA-A2-peptide pentamer staining and flow cytometry, Europium release cytotoxicity assays, and interferon-gamma and perforin ELIspot assays, using known HLA-A2 restricted peptide epitopes of the TAAs. The hybrid cell lines induced ASCTLs to the 4 selected TAAs, after 4 rounds of in vitro stimulation with the hybrid cell lines, in PBMCs from both (HLA-A2+) healthy donors and MM patients. In contrast, the (HLA-A2+) myeloma cell line, U266, failed to activate ASCTL in vitro. Hybrid cell lines, generated by fusion of EBV B-LCL and myeloma tumour cells, can induce ASCTL in PBMCs from healthy individuals and multiple myeloma patients in vitro, and may represent a novel strategy for use in immunotherapy of MM.
Supervisor: Browning, Michael ; Stover, Cordula Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.724438  DOI: Not available
Share: